Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.64 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.64 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.64 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.48 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3187909 | 0.90 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL26933627 | 0.90 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL2452394 | 0.89 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL3174914 | 0.88 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL2361698 | 0.88 | JAK2 (0.66) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL13532240 | 0.88 | JAK2 (0.50) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL4420318 | 0.88 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL15025600 | 0.88 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL15007939 | 0.88 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL15006941 | 0.88 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3999057-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES SAS (FR) | 2022-05-25 | — | — | EP | disclosed |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-1970375-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1970375-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | UROD, UTS2R, SLC14A1 | MAPK14 500/4885MAPK13 593/4885MAPK12 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.